Key result
A review of perioperative management of antithrombotic drugs in ophthalmic surgery provides recommendations for their continuation, cessation, and re-commencement to minimize bleeding and thrombotic risks.
Why the study?
How should antiplatelet and anticoagulant drugs be managed perioperatively in patients undergoing ophthalmic surgery to minimize bleeding and thrombotic complications?
How should antiplatelet and anticoagulant drugs be managed perioperatively in patients undergoing ophthalmic surgery to minimize bleeding and thrombotic complications?
This review provides practical guidance on managing antithrombotic therapy in patients undergoing various ophthalmic surgeries to balance bleeding and thrombotic risks.
Answers are grounded in this paper and cite their sources.
Supports individualized antithrombotic decisions in ophthalmic surgery; leaves open need for prospective validation.
The changing profile of patients undergoing ophthalmic surgery, with an increase in prevalence of antiplatelet and anticoagulant drug use, predisposes to bleeding complications. This mandates an awareness of these agents, allowing optimal patient management. We review traditional and newer agents in the context of cataract, vitreoretinal, glaucoma and oculoplastic surgery. Recommendations are given for continuation, cessation and re-commencement of these agents in order to minimise the risk of bleeding and thrombotic/thromboembolic complications.
No takes yet. Share an insight, caveat, or question.
Junaid Khan (2014) conducted a review in Ophthalmic surgery in patients on antithrombotic drugs. Perioperative management of antithrombotic drugs was evaluated. A review of perioperative management of antithrombotic drugs in ophthalmic surgery provides recommendations for their continuation, cessation, and re-commencement to minimize bleeding and thrombotic risks.
Synapse has enriched 10 related papers. Consider them for comparative context: